#

+91-9811715635

  • #
  • #
  • #
#

The US Long Acting Analgesic Market: Size, Trends & Forecasts (2017-2021)

Publish Date:Nov 2017
No. of Pages:51

Format : Adobe Reader (PDF) Instant delivery

US$ 800.00

Scope of the Report

The report entitled “The US Long Acting Analgesic Market: Size, Trends & Forecasts (2017-2021)”, provides analysis of the US analgesics market, with detailed analysis of market size in terms of number of procedures, segments, etc. Further, an analysis of the long acting analgesics in terms of penetration has been done for EXPAREL and HTX-011 along with its respective sales analysis. Under competitive landscape, players in the US analgesics market (both short and long acting analgesics) have been compared on the basis of market capitalization.

Moreover, the report assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the long acting analgesics market in the US has also been forecasted for the years 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Pacira Pharmaceutical Inc., Heron Therapeutics Inc. and Fresenius Group are some of the key players operating in the US long acting analgesics market whose company profiling is done in the report. In this segment of the report, business overview, financial overview and the business strategies of the companies are provided.

Company Coverage

Heron Therapeutics Inc.
Pacira Pharmaceutical Plc.
Fresenius Group

  Executive Summary

Analgesics (also known as painkillers) are the drugs that are used with the purpose of getting relief from acute and chronic pain. The pain relief in the case of analgesics takes place without loss of consciousness, in contrast to an anesthetic, which is a substance that imparts insensitivity to pain with the help of unconsciousness and elimination of sensory awareness.

The US analgesic market can be divided on the basis of type, mode of administration and duration. On the basis of type, the market can be sub segmented into opioid and non opioid. On the basis of mode of administration, the market can be divided into intravenous and locally delivered analgesics. On the basis of duration, the market can be further segmented into long acting and short acting analgesics.

The US long acting analgesic market is expected to increase at high growth rates during the forecast period (2017-2021). The US long acting analgesic market is supported by various growth factors such as increasing elderly population,, increase in use of non opioid analgesics especially in orthopedic procedures and disadvantages of opioids.

However, issues faced by PCRX in the commercialization of EXPAREL is major challenge faced by the market. Upsurge in research and development expenses, low penetration of currently used local analgesics, evolution of multimodal analgesics and long acting analgesics in pipeline are some of the latest trends existing in the market.

1. Executive Summary

2. Introduction

2.1 Post Operative Pain: An Overview
2.2 Analgesics: An Overview
2.3 Analgesics: Segments Overview
2.4 Long Acting Analgesics: An Overview

3. The US Market Analysis

3.1 The US Analgesic Market: An Analysis 

3.1.1 The US Analgesic Market by Number of Procedures 
3.1.2 The US Analgesic Market Procedures by Segments
3.1.3 The US Analgesic Market by Number of Orthopedic Procedures 
3.1.4 The US Analgesic Market by Number of Soft Tissue  Procedures 
3.1.5 The US Analgesic Market by Number of Nerve Block Procedures 
3.1.6 The US Analgesic Market by Generics and Other Brands Penetration

3.2 The US Long Acting Analgesic Market: An Analysis 

3.2.1 The US Long Acting Analgesic Market by Penetration
3.2.2 The US Long Acting Analgesic Market by EXPAREL Penetration
3.2.3 The US Long Acting Analgesic Market by EXPAREL Sales
3.2.4 The US Long Acting Market by HTX-011 Penetration
3.2.5 The US Long Acting Analgesic Market by HTX-011 Sales

4. Market Dynamics

4.1 Growth Drivers 
4.1.1 Increasing Ageing Population
4.1.2 Disadvantages of Opioids 
4.1.3 Upsurge in Use of Non Opioid Analgesics in Orthopedic Procedures

4.2 Challenges
4.2.1 Challenges in Commercialization of Exparel 

4.3 Market Trends
4.3.1 Increase in Research and Development Expenses 
4.3.2 Evolution of Multimodal Analgesics 
4.3.3 Long Acting Analgesics in Pipeline
4.3.4 Low Penetration of Currently Used Local Analgesics 

5. Competitive Landscape 

5.1 The US Analgesic Market: Players Comparison

6. Company Profiles

6.1 Pacira Pharmaceutical, Inc. (EXPAREL)
6.1.1 Business Overview 
6.1.2 Financial Overview 
6.1.3 Business Strategy 

6.2 Heron Therapeutics Inc. (HTX-011)
6.2.1 Business Overview 
6.2.2 Financial Overview 
6.2.3 Business Strategy 

6.3 Fresenius Group (NAROPIN)
6.3.1 Business Overview 
6.3.2 Financial Overview 
6.3.3 Business Strategy 
Figure 1: Analgesics Segments
Figure 2: The US Analgesic Market by Number of Procedures; 2016-2021 (million)
Figure 3: The US Analgesic Market Procedures by Segments; 2016 (Percentage,%)
Figure 4: The US Analgesic Market by Number of Orthopedic Procedures; 2016-2021(Million)
Figure 5: The US Analgesic Market by Number of Soft Tissue Procedures;2016 2021(Million)
Figure 6: The US Analgesic Market by Number of Nerve Block Procedures;2016-2021(Million)
Figure 7: The US Analgesic Market by Generic and Other Brands Penetration;2016-2021 (Percentage,%)
Figure 8: The US Long Acting Analgesic Market by Penetration; 2016-2021(Percentage,%)
Figure 9: The US Long Acting Analgesic Market by EXPAREL Penetration;2016-2021 (Percentage,%)
Figure 10: The US Long Acting Analgesic Market by EXPAREL Sales; 2012-2016 (US$ Million)
Figure 11: US Long Acting Analgesic Market by EXPAREL Sales; 2017-2021 (US$ Million)
Figure 12:The US Long Acting Analgesic Market by HTX-011 Penetration; 2016-2021 (Percentage,%)
Figure 13: US Long Acting Analgesic Market by HTX-011 Sales; 2019-2021 (US$ Million)
Figure 14: The US Ageing Population (65 Years and Above); 2012-2016 (Million)
Figure 15: Pacira Pharmaceutical Revenues; 2012-2016 (US$ Million)
Figure16:Pacira Pharmaceutical Research and Development Expenses; 2012-2016(US$ Million)
Figure17: Heron Therapeutics Research and Development Expenses;2012-2016(US$ Million)
Figure 18: Fresenius Sales; 2012-2016 (US$ Billion)
Figure 19: Fresenius Sales by Segments; 2016 (Percentage,%)
Table 1: Analgesics Segments: On the Basis of Type
Table 2: Analgesics Segments: On the Basis of Duration
Table 3: Analgesics Segments: On the Basis of Mode of Administration
Table 4: List of Procedure Making Use of Long Acting Procedures
Table 5: Long Acting Analgesics Under Development
Table 6:The US Analgesic Market Players Comparison